Willingness to use a drug consumption room among people who use drugs in Lyon, France, a city with no open scene of drug use (the TRABOUL survey).


Journal

Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624

Informations de publication

Date de publication:
16 10 2023
Historique:
received: 22 03 2023
accepted: 09 10 2023
medline: 23 10 2023
pubmed: 17 10 2023
entrez: 16 10 2023
Statut: epublish

Résumé

Drug consumption rooms (DCRs) have been developed in cities with open drug scenes, with the aim to reduce drug-related harm. In Lyon, France's second-largest city, there is no distinct drug use area, which raised doubts regarding the need for a DCR. We conducted a face-to-face survey of 264 people who use drugs (PWUDs), recruited in harm reduction or addiction treatment centers, in the streets or in squats. We assess their willingness to use a DCR, and we collected sociodemographic and medical features. Bivariable comparisons and analyses adjusted for sociodemographic parameters explored the association between willing to use a DCR and other variables, thus providing crude (ORs) and adjusted odds ratios (aORs) and 95% confidence intervals (95% CI). In total, 193 (73.1%) PWUDs accepted to participate (mean age 38.5 ± 9.3 years; 80.3% men). Among them, 64.2% declared willing to use a DCR. Being treatment-seeker (aOR 0.20, 95% CI [0.08-0.51]; p < 0.001) and not living alone (aOR 0.29; 95% CI [0.10-0.86], p = 0.025) were negatively associated with willing to use a DCR. By contrast, receiving precarity social insurance (aOR 4.12; 95% CI [1.86-9.14], p < 0.001), being seropositive for hepatitis C (aOR 3.60; 95% CI [1.20-10.84], p = 0.022), being cannabis user (aOR 2.45; 95% CI [1.01-5.99], p = 0.049), and reporting previous problems with residents (aOR 5.99; 95% CI [2.16-16.58], p < 0.001) or with the police (aOR = 4.85; 95% CI [1.43-16.39], p = 0.011) were positively associated. PWUDs, especially the most precarious ones, largely supported the opening of a DCR in Lyon, a city with no open drug scene.

Sections du résumé

BACKGROUND
Drug consumption rooms (DCRs) have been developed in cities with open drug scenes, with the aim to reduce drug-related harm. In Lyon, France's second-largest city, there is no distinct drug use area, which raised doubts regarding the need for a DCR.
METHODS
We conducted a face-to-face survey of 264 people who use drugs (PWUDs), recruited in harm reduction or addiction treatment centers, in the streets or in squats. We assess their willingness to use a DCR, and we collected sociodemographic and medical features. Bivariable comparisons and analyses adjusted for sociodemographic parameters explored the association between willing to use a DCR and other variables, thus providing crude (ORs) and adjusted odds ratios (aORs) and 95% confidence intervals (95% CI).
RESULTS
In total, 193 (73.1%) PWUDs accepted to participate (mean age 38.5 ± 9.3 years; 80.3% men). Among them, 64.2% declared willing to use a DCR. Being treatment-seeker (aOR 0.20, 95% CI [0.08-0.51]; p < 0.001) and not living alone (aOR 0.29; 95% CI [0.10-0.86], p = 0.025) were negatively associated with willing to use a DCR. By contrast, receiving precarity social insurance (aOR 4.12; 95% CI [1.86-9.14], p < 0.001), being seropositive for hepatitis C (aOR 3.60; 95% CI [1.20-10.84], p = 0.022), being cannabis user (aOR 2.45; 95% CI [1.01-5.99], p = 0.049), and reporting previous problems with residents (aOR 5.99; 95% CI [2.16-16.58], p < 0.001) or with the police (aOR = 4.85; 95% CI [1.43-16.39], p = 0.011) were positively associated.
CONCLUSIONS
PWUDs, especially the most precarious ones, largely supported the opening of a DCR in Lyon, a city with no open drug scene.

Identifiants

pubmed: 37845698
doi: 10.1186/s12954-023-00887-7
pii: 10.1186/s12954-023-00887-7
pmc: PMC10580523
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

149

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Potier C, Laprévote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48–68.
doi: 10.1016/j.drugalcdep.2014.10.012 pubmed: 25456324
European Monitoring Center for Drugs and Drug Addiction. Drug consumption rooms: an overview of provision and evidence. 2018. https://www.emcdda.europa.eu/publications/pods/drug-consumption-rooms_en . Accessed Oct 1, 2023.
Bourque S, Pijl EM, Mason E, Manning J, Motz T. Supervised inhalation is an important part of supervised consumption services. Can J Public Health. 2019;110(2):210–5.
doi: 10.17269/s41997-019-00180-w pubmed: 30725386 pmcid: 6964381
Scherbaum N, Specka M, Bombeck J, Marrziniak B. Drug consumption facility as part of a primary health care centre for problem drug users - which clients are attracted? Int J Drug Policy. 2009;20(5):447–9.
doi: 10.1016/j.drugpo.2009.01.001 pubmed: 19269803
Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26(Suppl 1):S5-11.
doi: 10.1016/j.drugpo.2014.11.007 pubmed: 25727260
Nguemeni Tiako MJ, Netherland J, Hansen H, Jauffret-Roustide M. Drug overdose epidemic colliding with COVID-19: what the United States can learn from France. Am J Public Health. 2022;112(S2):S128–32.
doi: 10.2105/AJPH.2022.306763 pubmed: 35349315 pmcid: 8965177
Jauffret-Roustide M, Pedrono G, Beltzer N. Supervised consumption rooms: the French paradox. Int J Drug Policy. 2013;6:628–30.
doi: 10.1016/j.drugpo.2013.05.008
French Government. [Décret n° 2005-1606 du 19 décembre 2005 relatif aux missions des centres d'accueil et d'accompagnement à la réduction des risques pour usagers de drogues et modifiant le code de la santé publique]. https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000000265437 . Accessed Oct 1, 2023.
French Government. [Arrêté du 22 mars 2016 portant approbation du cahier des charges national relatif à l'expérimentation d'espaces de réduction des risques par usage supervisé, autrement appelés « salles de consommation à moindre risque »]. https://www.legifrance.gouv.fr/loda/id/JORFTEXT000032291220/ . Accessed Oct 1, 2023.
Jauffret-Roustide M, Cailbault I. Drug consumption rooms: comparing times, spaces and actors in issues of social acceptability in French public debate. Int J Drug Policy. 2018;56:208–17.
doi: 10.1016/j.drugpo.2018.04.014 pubmed: 29754895
Roux P, Jauffret-Roustide M, Donadille C, Briand Madrid L, Denis C, Célérier I, Chauvin C, Hamelin N, Maradan G, Carrieri MP, Protopopescu C, Lalanne L, Auriacombe M, COSINUS Study Group. Impact of drug consumption rooms on non-fatal overdoses, abscesses and emergency department visits in people who inject drugs in France: results from the COSINUS cohort. Int J Epidemiol. 2022. https://doi.org/10.1093/ije/dyac120 .
doi: 10.1093/ije/dyac120
Lalanne L, Roux P, Donadille C, Briand Madrid L, Célerier I, Chauvin C, Hamelin N, Kervran C, Maradan G, Auriacombe M, Jauffret-Roustide M, COSINUS Study Group. Drug consumption rooms, an effective disposal to reduce at-risk practices associated to HIV/HCV infections among People who inject drugs Results from the COSINUS cohort study. Addiction. 2023. https://doi.org/10.1111/add.16320 .
doi: 10.1111/add.16320 pubmed: 37743675
Tissot N. Synthèse de Tendances Récents et Nouvelles Drogues (TREND) [Summary of Recent Trends and New Drugs] 2021: Lyon. https://www.ofdt.fr/ofdt/fr/trend/syntheseTREND2021_Lyon.pdf . Accessed Oct 1, 2023.
Bless R, Korf DJ, Freeman M. Open drug scenes: a cross-national comparison of concepts and urban strategies. Eur Addict Res. 1995;1(3):128–38.
doi: 10.1159/000259053
Eiden C, Vincent M, Serrand C, Serre A, Richard N, Picot MC, Frauger E, Fouilhé N, Daveluy A, Peyrière H, French Addictovigilance Network (FAN). Health consequences of cocaine use in France: data from the French Addictovigilance Network. Fundam Clin Pharmacol. 2021;35(2):455–65.
doi: 10.1111/fcp.12603 pubmed: 32854152
Cleirec G, Fortias M, Bloch V, Clergue-Duval V, Bellivier F, Dusouchet T, Debaulieu C, Vorspan F. Opinion of health professionals and drug users before the forthcoming opening of the first drug consumption room in Paris: a quantitative cross-sectional study. Harm Reduct J. 2018;15(1):53.
doi: 10.1186/s12954-018-0260-8 pubmed: 30359272 pmcid: 6202864
Briand Madrid L, Donadille C, Célerier I, Gutowski M, Grelli N, Maradan G, Jauffret-Roustide M, Lalanne L, Auriacombe M, Roux P, le groupe de recherche Cosinus. Drug consumption rooms: opinion and willingness among people who inject drugs in Marseille, France. Rev Epidemiol Sante Publique. 2023;71(1):1014.
Mitra S, Rachlis B, Scheim A, et al. Acceptability and design preferences of supervised injection services among people who inject drugs in a mid-sized Canadian City. Harm Reduct J. 2017;14:46.
doi: 10.1186/s12954-017-0174-x pubmed: 28709471 pmcid: 5513355
Mitra S, Rachlis B, Krysowaty B, et al. Potential use of supervised injection services among people who inject drugs in a remote and mid-size Canadian setting. BMC Public Health. 2019;19:284.
doi: 10.1186/s12889-019-6606-7 pubmed: 30849946 pmcid: 6408761
Taylor H, Curado A, Tavares J, Oliveira M, Gautier D, Maria JS. Prospective client survey and participatory process ahead of opening a mobile drug consumption room in Lisbon. Harm Reduct J. 2019;16(1):49.
doi: 10.1186/s12954-019-0319-1 pubmed: 31399097 pmcid: 6688324
Harris RE, Richardson J, Frasso R, Anderson ED. Perceptions about supervised injection facilities among people who inject drugs in Philadelphia. Int J Drug Policy. 2018;52:56–61.
doi: 10.1016/j.drugpo.2017.11.005 pubmed: 29241143
Duncan E, Shufelt S, Barranco M, Udo T. Acceptability of supervised injection facilities among persons who inject drugs in upstate New York. Harm Reduct J. 2022;19(1):87.
doi: 10.1186/s12954-022-00665-x pubmed: 35907854 pmcid: 9338679
Observatoire Français des Drogues et Tendances addictives (OFDT). Rapport National à l’EMCDDA [National Report to the EMCDDA], 2022 https://www.ofdt.fr/ofdt/reitox/rapports-nationaux/ . Accessed Oct 1, 2023.
Cadet-Taïrou A, Gandilhon M. Jangal C, Dambélé S, Jauffret-Roustide M. Résultats de l’étude Crack en Ile de France, Note Inserm-OFDT, janvier 2021. https://www.ofdt.fr/publications/collections/resultats/synthese-des-principaux-resultats-de-letude-crack-en-ile-de-france/ . Accessed Oct 1, 2023

Auteurs

Mathieu Chappuy (M)

Service d'Hépatologie et d'Addictologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
Service Universitaire d'Addictologie de Lyon (SUAL), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon K, 5 Place d'Arsonval, 69002, Lyon, France.
Service Universitaire d'Addictologie de Lyon (SUAL), CH Le Vinatier, Bron, France.
Service Pharmaceutique, Hospices Civils de Lyon, Lyon, France.

Philippe Lack (P)

Service d'Hépatologie et d'Addictologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.

Baptiste David (B)

Service d'Hépatologie et d'Addictologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.

Gilles Penavayre (G)

Association Aria Oppélia, Villeurbanne, France.

Damien Thabourey (D)

Association Aria Oppélia, Villeurbanne, France.

Maira Landulpho (M)

Association Aria Oppélia, Villeurbanne, France.

Anthony Plasse (A)

CAARUD Pause Diabolo, Association le Mas, Lyon, France.

Christophe Icard (C)

Service Universitaire d'Addictologie de Lyon (SUAL), CH Le Vinatier, Bron, France.

François Bailly (F)

Service d'Hépatologie et d'Addictologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.

Faroudja Boutahra (F)

SMPR de Corbas, Pôle SMDPL, CH Le Vinatier, Bron, France.

Pierre Pradat (P)

Centre de Recherche Clinique, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.

Marianne Maynard (M)

Centre de Recherche Clinique, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.

Marie Jauffret-Roustide (M)

Centre d'Étude Des Mouvements Sociaux (Inserm U1276/CNRS UMR 8044/EHESS), Paris, France.
British Columbia Center on Substance Use (BCCSU), British Columbia University, Vancouver, Canada.
Baldy Center on Law and Social Policy, Buffalo University, Buffalo, USA.

Julia de Ternay (J)

Service Universitaire d'Addictologie de Lyon (SUAL), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon K, 5 Place d'Arsonval, 69002, Lyon, France.
Univ. Lyon, UCBL1, INSERM U1028, CNRS UMR5292, CRNL, PSYR2, Lyon, France.

Benjamin Rolland (B)

Service Universitaire d'Addictologie de Lyon (SUAL), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon K, 5 Place d'Arsonval, 69002, Lyon, France. benjrolland@gmail.com.
Service Universitaire d'Addictologie de Lyon (SUAL), CH Le Vinatier, Bron, France. benjrolland@gmail.com.
Univ. Lyon, UCBL1, INSERM U1028, CNRS UMR5292, CRNL, PSYR2, Lyon, France. benjrolland@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH